Skip to main content

Drug Interactions between hepatitis b adult vaccine and sars-cov-2 mrna (tozinameran-tris-sucrose) vaccine

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

hepatitis B adult vaccine SARS-CoV-2 mRNA (tozinameran-tris-sucrose) vaccine

Applies to: hepatitis b adult vaccine and sars-cov-2 mrna (tozinameran-tris-sucrose) vaccine

MONITOR: The safety, immunogenicity, and efficacy of SARS-CoV-2 (COVID-19) vaccines when administered concurrently with other vaccines have not been extensively studied. Experience with non-COVID-19 vaccines has demonstrated that immunogenicity and adverse event profiles are generally similar when vaccines are administered simultaneously compared to when they are given alone. A study of inactivated influenza vaccines coadministered with the AstraZeneca or Pfizer BioNTech COVID-19 vaccine reported acceptable immunogenicity and reactogenicity, without any additional safety concerns. In a separate study, coadministration of the Novavax COVID-19 vaccine with inactivated influenza vaccine did reveal some attenuation of the antibody response to COVID-19 but was still associated with high efficacy against COVID-19. Additionally, the results of a study examining the administration of a Moderna COVID-19 booster vaccine given concomitantly with recombinant zoster vaccine versus separated by 2 weeks revealed immunological noninferiority and a similar safety and reactogenicity profile in adults 50 years of age and older. Clinical data are not available for all the possible vaccine combinations; however, available data suggest that COVID-19 vaccines may be coadministered with most other vaccines when necessary.

MANAGEMENT: The U.S. Centers for Disease Control and Prevention (CDC) advises that COVID-19 vaccines and other vaccines may now be administered without regard to timing, including simultaneous administration on the same day as well as coadministration within 14 days. COVID-19 vaccines should not be mixed with any other vaccine in the same syringe or vial. If multiple vaccines are administered during a single visit, each injection should be administered at a different injection site. For adolescents and adults, the deltoid muscle can be used for more than one intramuscular injection, but each injection should be separated by 1 inch or more if possible. It is also advisable to administer COVID-19 vaccines and vaccines that may be more likely to cause a local reaction (e.g., tetanus toxoid-containing and adjuvanted vaccines) in different limbs whenever possible. Current local immunization guidelines and prescribing information for individual vaccines should be consulted for more specific recommendations.

References

  1. US Food and Drug Administration "Emergency Use Authorization. Emergency Use Authorization (EUA) information, and list of all current EUAs. https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization" (2020):
  2. CDC Centers for Disease Control and Prevention "Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States. https://www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html" (2022):
  3. Centers for Disease Control and Prevention "Use of COVID-19 vaccines in the U.S. https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html" (2023):
  4. UK Health Security Agency "COVID-19: the green book, chapter 14a https://www.gov.uk/government/publications/covid-19-the-green-book-chapter-14a" (2023):
  5. Public Health Agency of Canada "Immunization of immunocompromised persons: Canadian immunization guide https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-3-vaccination-specific-populations/page-8-immunization-immunocompromised-p" (2023):
  6. Australian Government. Department of Health and Aged Care "Australian immunisation handbook: COVID-19. https://immunisationhandbook.health.gov.au/contents/vaccine-preventable-diseases/covid-19" (2023):
  7. Lazarus R, Baos S, Cappel-Porter H, et al. "Safety and immunogenicity of concomitant administration of COVID-19 vaccines (ChAdOx1 or BNT162b2) with seasonal influenza vaccines in adults in the UK (ComFluCOV): a multicentre, randomised, controlled, phase 4 trial." Lancet 398 (2021): 2277-87
  8. Naficy A, Kuxhausen A, Pirrotta P, et al. "No immunological interference or safety concerns when adjuvanted recombinant zoster vaccine is coadministered with a coronavirus disease 2019 mRNA-1273 booster vaccine in adults aged 50 years and older: a randomized trial." Clin Infect Dis 77 (2023): 1238-46
  9. Centers for Disease Control and Prevention (CDC) "HAN Title. Distributed via the CDC Health Alert Network September 05, 2023, 2:00 PM ET. CDCHAN-00498. https://emergency.cdc.gov/han/2023/han00498.asp" (2023):
  10. Centers for Disease Control and Prevention (CDC) "Vaccine administration. General best practice guidelines for immunization. https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/administration.html" (2023):
View all 10 references

Switch to consumer interaction data

Drug and food interactions

No alcohol/food interactions were found. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer